MX2008013057A - Proteinas de enlace que comprenden regiones bisagra y regiones fc de inmunoglobulina que tienen funciones efectoras fc alteradas. - Google Patents

Proteinas de enlace que comprenden regiones bisagra y regiones fc de inmunoglobulina que tienen funciones efectoras fc alteradas.

Info

Publication number
MX2008013057A
MX2008013057A MX2008013057A MX2008013057A MX2008013057A MX 2008013057 A MX2008013057 A MX 2008013057A MX 2008013057 A MX2008013057 A MX 2008013057A MX 2008013057 A MX2008013057 A MX 2008013057A MX 2008013057 A MX2008013057 A MX 2008013057A
Authority
MX
Mexico
Prior art keywords
binding
binding proteins
hinge
domain
altered
Prior art date
Application number
MX2008013057A
Other languages
English (en)
Inventor
Baum Peter Robert
Erik Stephen Espling
Tan Phillip
Thompson Peter Armstrong
Original Assignee
Trubion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trubion Pharmaceuticals Inc filed Critical Trubion Pharmaceuticals Inc
Publication of MX2008013057A publication Critical patent/MX2008013057A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proveen proteínas de enlace que comprenden una o más de bisagra de inmunoglobulina de región Fc, y/o dominio CR3 y/o CR2 en donde una o más bisagras y/o región constante CH2 y/o dominio CH3 se modifica para alterar la afinidad de enlace de las proteínas de enlace y/o especificidad para un receptor cognado (e.g. un receptor Fc) y/o para proveer una o más especificidades de enlace nuevas a la bisagra y/o región constante que la inmunoglobulina sin modificar correspondiente no posee (e.g. afinidad para distintas clases de receptor cognado distinta de la clase de receptor cognado a la cual se enlaza específicamente la proteína de enlace sin modificar). Las proteínas de enlace de conformidad con la presente invención incluyen, por ejemplo, anticuerpos modificados, fragmentos de anticuerpos, proteínas de enlace recombinantes y proteínas de fusión dominio de enlace- inmunoglobulina molecularmente modificadas, incluyendo pequeños productos inmunofarmacéuticos modulares.
MX2008013057A 2006-04-14 2007-04-13 Proteinas de enlace que comprenden regiones bisagra y regiones fc de inmunoglobulina que tienen funciones efectoras fc alteradas. MX2008013057A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74489906P 2006-04-14 2006-04-14
PCT/US2007/066634 WO2007121354A2 (en) 2006-04-14 2007-04-13 Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions

Publications (1)

Publication Number Publication Date
MX2008013057A true MX2008013057A (es) 2009-04-07

Family

ID=38610404

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008013057A MX2008013057A (es) 2006-04-14 2007-04-13 Proteinas de enlace que comprenden regiones bisagra y regiones fc de inmunoglobulina que tienen funciones efectoras fc alteradas.

Country Status (9)

Country Link
US (1) US20080227958A1 (es)
EP (1) EP2007808A4 (es)
JP (1) JP2009538273A (es)
CN (1) CN101466733A (es)
AU (1) AU2007238034A1 (es)
BR (1) BRPI0710011A2 (es)
CA (1) CA2648849A1 (es)
MX (1) MX2008013057A (es)
WO (1) WO2007121354A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1772465E (pt) 2005-01-05 2009-05-21 F Star Biotech Forsch & Entw Domínios de imunoglobulina sintética com propriedades de ligação construídos em regiões da molécula diferentes das regiões determinantes de complementaridade
US7981414B2 (en) * 2005-12-20 2011-07-19 Cephalon Australia Pty Ltd Anti-inflammatory dAb
AU2007211829C9 (en) 2006-02-01 2013-07-11 Cephalon Australia Pty Ltd Domain antibody construct
AT503889B1 (de) * 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
US7846434B2 (en) * 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
CN101802006B (zh) 2007-06-26 2013-08-14 F-星生物技术研究与开发有限公司 展示结合剂
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
CN106399276B (zh) 2009-11-02 2021-08-10 华盛顿大学 治疗性核酸酶组合物和方法
KR102596953B1 (ko) 2011-04-29 2023-11-02 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료적 뉴클레아제 조성물 및 방법
US20140369934A1 (en) 2011-06-02 2014-12-18 Massachusetts Institute Of Technology dsRNA/DNA Hybrid Genome Replication Intermediate Of Metakaryotic Stem Cells
FR2980271B1 (fr) * 2011-09-16 2013-10-11 Cisbio Bioassays Procede de determination de la glycosylation d'un anticorps
CN104507967B (zh) 2012-01-20 2018-10-12 建新公司 抗cxcr3抗体
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
JP6628966B2 (ja) * 2012-06-14 2020-01-15 中外製薬株式会社 改変されたＦｃ領域を含む抗原結合分子
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP2953972B1 (en) 2013-02-05 2020-07-08 EngMab Sàrl Method for the selection of antibodies against bcma
US10132816B2 (en) 2013-03-14 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Measurement of FGF21 as a biomarker of fructose metabolism
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
CA2912312C (en) 2013-05-20 2023-01-24 Board Of Trustees Of The University Of Arkansas Gep5 model for multiple myeloma
WO2015066550A1 (en) 2013-10-31 2015-05-07 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods
EP3070168A4 (en) 2013-11-11 2017-06-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
ES2913205T3 (es) 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
AU2015329965A1 (en) 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1
AU2015343048A1 (en) * 2014-11-06 2017-05-18 Children's Research Institute, Children's National Medical Center Immunotherapeutics for cancer and autoimmune diseases
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
EP3276002B1 (en) * 2015-03-26 2020-04-29 JSR Corporation Immunoglobulin-binding protein and affinity carrier using same
PT3331910T (pt) 2015-08-03 2020-03-24 Engmab Sarl Anticorpos monoclonais contra o antigénio de maturação de células b (bcma) humano
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
US11618784B2 (en) 2016-07-19 2023-04-04 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD47 combination therapy
CN110167964B (zh) 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
JP6550413B2 (ja) * 2017-02-24 2019-07-24 アール−ファーム・インターナショナル・リミテッド・ライアビリティ・カンパニーＲ−Ｐｈａｒｍ Ｉｎｔｅｒｎａｔｉｏｎａｌ， Ｌｌｃ オステオプロテゲリン由来の組成物およびその使用
CN110352074A (zh) 2017-02-28 2019-10-18 西雅图遗传学公司 用于偶联的半胱氨酸突变抗体
EP3720963A4 (en) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha ANTIGEN BINDING MOLECULE INCLUDING A VARIABLE REGION OF MODIFIED ANTIBODIES BINDING TO CD3 AND CD137
GB201804243D0 (en) * 2018-03-16 2018-05-02 Liverpool School Tropical Medicine Hinge sequences
US20210380700A1 (en) * 2018-07-06 2021-12-09 Abmax Biopharmaceuticals De-adcc/cdc functions of antibodies and their applications
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
CN112210005B (zh) * 2019-07-11 2024-03-26 京天成生物技术(北京)有限公司 低免疫原性低adcc/cdc功能的抗c5人源化单抗及其应用
NZ784956A (en) 2019-07-18 2023-01-27 Hanmi Pharm Ind Co Ltd Novel method for preparing long-acting drug conjugate through preparation of intermediate
US11274151B2 (en) 2020-03-31 2022-03-15 Chugai Seiyaku Kabushiki Kaisha CD3-targeting and DLL3-targeting multispecific antigen-binding molecules and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888773A (en) * 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7355008B2 (en) * 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same

Also Published As

Publication number Publication date
EP2007808A2 (en) 2008-12-31
EP2007808A4 (en) 2010-07-21
WO2007121354A2 (en) 2007-10-25
AU2007238034A1 (en) 2007-10-25
BRPI0710011A2 (pt) 2011-08-02
CA2648849A1 (en) 2007-10-25
JP2009538273A (ja) 2009-11-05
WO2007121354A3 (en) 2008-12-11
CN101466733A (zh) 2009-06-24
US20080227958A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
MX2008013057A (es) Proteinas de enlace que comprenden regiones bisagra y regiones fc de inmunoglobulina que tienen funciones efectoras fc alteradas.
WO2006023420A3 (en) Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
DK1709081T3 (da) Fusionspolypeptider, der kan aktivere receptorer
NZ596865A (en) Single-chain multivalent binding proteins with effector function
UA86605C2 (ru) Антитело, которое содержит вариант исходного человеческого fс-участка
AU2018272852A8 (en) Antibodies comprising modified heavy constant regions
PT2173381E (pt) Polipéptidos que se ligam ao receptor fc, com funções efectivadoras modificadas
EA200970515A1 (ru) МОДИФИЦИРОВАННЫЕ РАСТВОРИМЫЕ СЛИТЫЕ КОНСТРУКЦИИ РЕЦЕПТОРА FGF И Fc С УЛУЧШЕННОЙ БИОЛОГИЧЕСКОЙ АКТИВНОСТЬЮ
EP2684889A3 (en) Multivariable antigens complexed with targeting humanized monoclonal antibody
NZ585622A (en) Hepatitis c virus antibodies
IN2015DN01361A (es)
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
NZ587198A (en) Monoclonal antibodies against the rgm a protein and uses thereof
WO2007106707A3 (en) Identification and engineering of antibodies with variant heavy chains and methods of using same
SE0401601D0 (sv) Protofibril specific antibodies and uses thereof
DK1562972T3 (da) Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
CY1108545T1 (el) Πρωτεϊνες υπομοναδας υποδοχεα κυτοκινης θηλαστικου, σχετικα αντιδραστηρια και μεθοδοι
WO2021041715A3 (en) Compositions including igg fc mutations and uses thereof
CY1109725T1 (el) Ειδικες δεσμευομενες πρωτεϊνες και χρησεις αυτων
IL200373A (en) A monoclonal antibody that binds to 3erbb and a pharmacological preparation that includes the same to inhibit 3erbb signaling in humans
EA201291181A1 (ru) Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
MX2010004660A (es) NUEVOS ANTICUERPOS ESPECIFICOS DE LOS PEPTIDOS ß-AMILOIDES Y SUS USOS COMO AGENTES DE DIAGNOSTICO Y DROGAS.
EP3300739A3 (en) Antibodies and related molecules that bind to 161p2f10b proteins
EA200870208A1 (ru) Конструкт однодоменного антитела

Legal Events

Date Code Title Description
FA Abandonment or withdrawal